Read + Share
. Correction to: DOP055 Efficacy and Safety Up to 3 Years of Risankizumab
Maintenance Treatment in Patients With Moderately to Severely Active Ulcerative
Colitis: Interim Results from Phase 3 COMMAND Open-Label Extension Study. J Crohns Colitis 2026;20:jjag042.
PMID: 41964941
|
 |
|
